Bank Of New York Mellon Corp Novavax Inc Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $2.4 Million - $6.78 Million	270,676 New	270,676 $2.78 Million
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $120,629 - $504,523	6,628 Added 2.16%	313,688 $5.71 Million
Q2 2022 Aug 15, 2022	BUY	$36.28 - $75.29 $683,442 - $1.42 Million	18,838 Added 6.54%	307,060 $15.8 Million
Q1 2022 May 11, 2022	SELL	$69.73 - $142.9 $168,328 - $344,960	-2,414 Reduced 0.83%	288,222 $21.2 Million
Q4 2021 Feb 11, 2022	BUY	$134.56 - $217.97 $265,083 - $429,400	1,970 Added 0.68%	290,636 $41.6 Million
Q3 2021 Nov 12, 2021	BUY	$177.8 - $270.58 $3.17 Million - $4.83 Million	17,852 Added 6.59%	288,666 $59.8 Million
Q2 2021 Aug 11, 2021	SELL	$121.0 - $257.67 $622,908 - $1.33 Million	-5,148 Reduced 1.87%	270,814 $57.5 Million
Q1 2021 May 13, 2021	SELL	$112.98 - $319.93 $2.7 Million - $7.65 Million	-23,913 Reduced 7.97%	275,962 $50 Million
Q4 2020 Feb 09, 2021	BUY	$78.74 - $139.5 $1.34 Million - $2.38 Million	17,052 Added 6.03%	299,875 $33.4 Million
Q3 2020 Nov 12, 2020	SELL	$79.44 - $178.51 $926,349 - $2.08 Million	-11,661 Reduced 3.96%	282,823 $30.6 Million
Q2 2020 Aug 12, 2020	BUY	$13.86 - $83.61 $1.8 Million - $10.9 Million	129,940 Added 78.97%	294,484 $24.5 Million
Q1 2020 May 06, 2020	BUY	$3.93 - $16.0 $140,273 - $571,088	35,693 Added 27.7%	164,544 $2.23 Million
Q4 2019 Feb 14, 2020	SELL	$3.69 - $5.22 $15,605 - $22,075	-4,229 Reduced 3.18%	128,851 $512,000
Q3 2019 Nov 07, 2019	BUY	$4.02 - $7.84 $122,614 - $239,127	30,501 Added 29.73%	133,080 $668,000
Q2 2019 Aug 12, 2019	BUY	$4.93 - $12.2 $505,714 - $1.25 Million	102,579 New	102,579 $601,000

Others Institutions Holding NVAX

# of Institutions

290

Shares Held

93.4M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account